Decitabine + cedazuridine

PBAC's latest decision on Decitabine + cedazuridine: Deferred (2021). Considered for Treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukaemia (CMML) in high-risk patients.

Eligible population

Adult patients with myelodysplastic syndrome classified as intermediate-2 or high-risk according to IPSS with ≤30% marrow blasts, and chronic myelomonocytic leukaemia patients with 10% to 29% marrow blasts without myeloproliferative disorder.

Therapy area

Haematology

Line of therapy

Any

Evidence base

RCT

Primary endpoint

Surrogate

Pivotal trial size

133 patients

Key trials

ASCERTAIN, ASTX727-01-B, Kantarjian 2006, Lubbert 2011, Fenaux 2009, Silverman 2002

Comparator

azacitidine

Economic model

Cost-minimisation

ICER note

Cost-minimisation analysis; no ICER calculated. Economic evaluation presented but not detailed in the public summary.

Similar precedents

• Decitabine with cedazuridine
  similarity 0.95
• Daunorubicin with cytarabine
  similarity 0.63
• Imatinib
  similarity 0.62
• Daunorubicin with cytarabine (liposomal)
  similarity 0.62
• Fedratinib
  similarity 0.61
• Venetoclax
  similarity 0.61